A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor.

Autor: Brown JA; GlaxoSmithKline R&D, Cambridge, MA, USA., Bal J; GlaxoSmithKline R&D Stevenage, Stevenage, UK., Simeoni M; GlaxoSmithKline, GSK House, Brentford, UK., Williams P; GlaxoSmithKline, GSK House, Brentford, UK., Mander PK; GlaxoSmithKline R&D Stevenage, Stevenage, UK., Soden PE; GlaxoSmithKline R&D Stevenage, Stevenage, UK., Daga S; GlaxoSmithKline, Uxbridge, UK., Fahy WA; GlaxoSmithKline, GSK House, Brentford, UK., Wong GK; GlaxoSmithKline R&D Stevenage, Stevenage, UK., Bloomer JC; GlaxoSmithKline R&D, Ware, Hertfordshire, UK., Erwig L; GlaxoSmithKline R&D Stevenage, Stevenage, UK.; Johnson & Johnson, London, UK., Cui Y; GlaxoSmithKline, GSK House, Brentford, UK., Fernando D; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Carnaghan H; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Banham-Hall EJ; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Hopkins S; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Davis BG; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Oliveira JJD; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Prinjha RK; GlaxoSmithKline R&D Stevenage, Stevenage, UK.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 May; Vol. 88 (5), pp. 2140-2155. Date of Electronic Publication: 2021 Dec 18.